Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about C1Q: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
C1Q is a gene implicated in neurodegeneration research. Key relationships include: activates, associated with, interacts with. Associated with AD, ALI, ALS. Connected to 856 entities in the SciDEX knowledge graph.
| Gene Symbol | C1Q |
| Full Name | c1q |
| Protein Type | Signaling Protein |
| Target Class | Signaling Protein |
| Function | Complement cascade inhibitor or antibody-mediated neutralization |
| Mechanism of Action | Complement cascade inhibitor or antibody-mediated neutralization |
| Primary Expression | Primarily expressed in myeloid cells (monocytes, macrophages, microglia); astrocytic expression detected in disease states |
| Subcellular Localization | synapses, dystrophic neurites, extracellular protein aggregates, and vascular interfaces. These features make C1QA a hig |
| Druggability | Low (0.36) |
| Clinical Stage | Approved |
| Molecular Weight | 26 kDa |
| Pathways | Chaperone, Complement, Differentiation, Endocytosis, Epigenetic |
| UniProt ID | P02745 |
| NCBI Gene ID | 712 |
| Ensembl ID | ENSG00000173372 |
| GeneCards | C1Q |
| Human Protein Atlas | C1Q |
| Associated Diseases | A1 Astrocytes, A1 Reactive Astrocytes, AD, AGING, ALI, AML |
| Known Drugs/Compounds | Beta-Amyloid Oligomers, β-amyloid Oligomers, RAPAMYCIN, β-Amyloid Oligomers, LPS, rapamycin |
| Interactions | C3, C1QA, C1QC, RAB11, RAB5, CNTNAP4 |
| SciDEX Target | View Target Profile (4 clinical trials) |
| KG Connections | 1529 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
C1Q["C1Q"] -->|"associated"| neurodegeneration["neurodegeneration"]
C1Q["C1Q"] -->|"interacts"| C3["C3"]
C1Q["C1Q"] -->|"co discussed"| NAMPT["NAMPT"]
C1Q["C1Q"] -->|"co discussed"| GPX4["GPX4"]
C1Q["C1Q"] -->|"co discussed"| PLA2G6["PLA2G6"]
C1Q["C1Q"] -->|"co discussed"| MMP2["MMP2"]
C3_1["C3"] -->|"interacts"| C1Q["C1Q"]
MMP9["MMP9"] -->|"co discussed"| C1Q["C1Q"]
SLC7A11["SLC7A11"] -->|"co discussed"| C1Q["C1Q"]
AQP4["AQP4"] -->|"co discussed"| C1Q["C1Q"]
style C1Q fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| CR3 | signals_through | receptor | 1.00 |
| MICROGLIA | activates | cell_type | 1.00 |
| PHAGOCYTOSIS | activates | phenotype | 1.00 |
| Complement | activates | pathway | 1.00 |
| Als | associated_with | disease | 1.00 |
| Synapse Loss | mediates | phenotype | 0.95 |
| A1 Astrocytes | associated_with | phenotype | 0.95 |
| Trained Immunity | modulates | process | 0.95 |
| Microglial Phagocytosis | mediates | process | 0.95 |
| Reactive Astrocytes | activates | cell_type | 0.95 |
| A1 Reactive Astrocytes | associated_with | phenotype | 0.95 |
| C3-Cr3 Signaling Pathway | activates | pathway | 0.95 |
| Tumor-Associated Macrophages | expressed_in | cell_type | 0.95 |
| Inflammation | activates | disease | 0.95 |
| Alzheimer | activates | disease | 0.95 |
| Tumor | associated_with | disease | 0.95 |
| Atherosclerosis | risk_factor_for | disease | 0.95 |
| ATHEROSCLEROSIS | associated_with | entity | 0.95 |
| Alzheimer's Disease | mediates | disease | 0.95 |
| Alzheimer'S Disease | involved_in | disease | 0.92 |
| Human Atherosclerotic Plaques | involved_in | phenotype | 0.90 |
| Microglial Synapse Engulfment | mediates | process | 0.90 |
| Synapse Loss | associated_with | phenotype | 0.90 |
| Classical Complement Cascade | activates | pathway | 0.90 |
| β-Amyloid Oligomer Toxicity | associated_with | mechanism | 0.90 |
| Synapse Elimination | mediates | process | 0.90 |
| Myeloid Cell Metabolism | associated_with | process | 0.90 |
| Microglial Synapse Engulfment | activates | process | 0.90 |
| Human Atherosclerotic Plaques | associated_with | disease | 0.90 |
| Microglial Phagocytosis Of Synapses | regulates | process | 0.90 |
| Synapse Loss | promotes | phenotype | 0.90 |
| ISCHEMIC STROKE | associated_with | entity | 0.90 |
| NEUROINFLAMMATION | mediates | entity | 0.90 |
| Phagocytosis | activates | pathway | 0.90 |
| Complement | inhibits | pathway | 0.90 |
| Inflammatory Reactivity | inhibits | phenotype | 0.88 |
| Beta-Amyloid Oligomers | interacts_with | compound | 0.88 |
| SYNAPSE_ELIMINATION | regulates | phenotype | 0.87 |
| Ischemic Stroke | associated_with | disease | 0.85 |
| Large Artery Atherosclerosis | biomarker_for | disease | 0.85 |
| Synaptic Pruning | involved_in | process | 0.85 |
| Excitatory Synapse Elimination | involved_in | process | 0.85 |
| Inhibitory Synapse Elimination | involved_in | process | 0.85 |
| NEUROCOGNITIVE DYSFUNCTION | contributes_to | entity | 0.85 |
| Atherosclerotic Plaques | associated_with | structure | 0.85 |
| Synaptic Tagging | involved_in | process | 0.85 |
| Retinal Ganglion Cell Dysfunction | promotes | phenotype | 0.85 |
| Synaptic Pruning | mediates | process | 0.85 |
| Clear Cell Renal Carcinoma | therapeutic_target | disease | 0.85 |
| Retinal Ganglion Cell Death | promotes | phenotype | 0.85 |
| Source | Relation | Type | Str |
|---|---|---|---|
| COMPLEMENT | activates | gene | 1.00 |
| MICROGLIA | associated_with | gene | 1.00 |
| ALZHEIMER'S DISEASE | associated_with | disease | 1.00 |
| NPTX2 | binds | protein | 0.95 |
| SPP1 | upregulates | entity | 0.90 |
| NEURODEGENERATION | associated_with | gene | 0.90 |
| h-58e4635a | targets_gene | hypothesis | 0.90 |
| h-89500d80 | targets_gene | hypothesis | 0.90 |
| β-Amyloid Oligomers | interacts_with | compound | 0.85 |
| TYROBP | regulates | protein | 0.85 |
| MICROGLIA | inhibits | gene | 0.82 |
| AMYLOID | associated_with | gene | 0.82 |
| h-58e4635a | targets | hypothesis | 0.80 |
| CD2AP | correlates_with | protein | 0.80 |
| SDA-2026-04-01-gap-013 | targets | analysis | 0.80 |
| OCULAR HYPERTENSION | upregulates | biological_process | 0.80 |
| MICROGLIA | secretes | cell_type | 0.80 |
| COMPLEMENT | regulates | gene | 0.80 |
| COMPLEMENT | inhibits | gene | 0.80 |
| ALZHEIMER | activates | gene | 0.80 |
| Microglia | associated_with | cell_type | 0.75 |
| Astrocytes | associated_with | cell_type | 0.75 |
| MICROGLIA | activates | cell_type | 0.74 |
| ASTROCYTES | associated_with | gene | 0.74 |
| NPTX2 | interacts_with | protein | 0.72 |
| MICROGLIA | expressed_in | cell_type | 0.72 |
| oxidized lipids | activates | process | 0.70 |
| APOE | interacts_with | protein | 0.70 |
| periodontal infection | activates | disease | 0.70 |
| ocular hypertension | activates | disease | 0.70 |
| C1QA | activates | gene | 0.70 |
| TAU | activates | gene | 0.70 |
| APOE | co_mentioned_with | gene | 0.70 |
| COMPLEMENT | biomarker_for | gene | 0.70 |
| NEURODEGENERATION | activates | gene | 0.70 |
| COMPLEMENT | associated_with | gene | 0.70 |
| CYTOKINES | activates | gene | 0.70 |
| COMPLEMENT | interacts_with | gene | 0.70 |
| NEURODEGENERATION | regulates | gene | 0.70 |
| AMYLOID | activates | gene | 0.70 |
| ALZHEIMER | regulates | gene | 0.70 |
| NEURODEGENERATIVE DISEASES | causes | gene | 0.70 |
| NEURODEGENERATIVE DISORDERS | activates | gene | 0.70 |
| NEURODEGENERATIVE DISEASES | activates | gene | 0.70 |
| h-89500d80 | targets | hypothesis | 0.70 |
| C3 | interacts_with | gene | 0.68 |
| BDNF | associated_with | gene | 0.66 |
| ASTROCYTES | activates | gene | 0.66 |
| NF-KB | associated_with | protein | 0.66 |
| MAFB | regulates | protein | 0.64 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Complement C1q Suppression as Mechanism Linking Exercise Pla | 0.560 | neurodegeneration | What are the specific circulating factor |
| TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimina | 0.520 | neurodegeneration | How do the seven novel ALS genes functio |
| C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV I | 0.497 | neurodegeneration | Are interneuron oscillation deficits com |
| Complement C1q Mimetic Decoy Therapy | 0.479 | neurodegeneration | Synaptic pruning by microglia in early A |
| Complement C1QA Inhibition Synergizes with PV Interneuron Mo | 0.473 | neurodegeneration | What molecular mechanisms underlie the d |
| C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction v | 0.455 | neurodegeneration | Why does PRKN-mediated mitophagy, typica |
| Complement C1q Subtype Switching | 0.437 | neurodegeneration | 4R-tau strain-specific spreading pattern |
| Complement C1QA Spatial Gradient in Cortical Layers | 0.428 | Alzheimer's Disease | SEA-AD Gene Expression Profiling — Allen |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-12 | 0 hypotheses
neurodegeneration | 2026-04-11 | 0 hypotheses
neurodegeneration | 2026-04-10 | 0 hypotheses
neurodegeneration | 2026-04-10 | 0 hypotheses
neurodegeneration | 2026-04-10 | 0 hypotheses
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Prolonged anesthesia induces neuroinflammation and complement-mediated microglia [PMID:36600274] | Xu F, Han L, Wang Y, Deng D, Ding Y, Zha | BMC Med | 2023 | 2 |
| Perivascular cells induce microglial phagocytic states and synaptic engulfment v [PMID:36747024] | De Schepper S, Ge JZ, Sierksma A, Crowle | Nat Neurosci | 2023 | 2 |
| An integrative analysis of single-cell and bulk transcriptome and bidirectional [PMID:38179058] | Cui HK, Tang CJ, Gao Y, Li ZA, Zhang J, | Front Immunol | 2023 | 2 |
| Early complement genes are associated with visual system degeneration in multipl [PMID:31289819] | Fitzgerald KC, Kim K, Smith MD, Aston SA | Brain | 2019 | 1 |
| Phosphoproteomics uncovers a neuroimmune perspective on trigeminal neuralgia: se [PMID:41853292] | Zhai X, Lin X, Zhang L, Ren Y, Miao H, M | Frontiers in immunology | 2026 | 0 |
| Proteomic Signature in Men with Central Serous Chorioretinopathy. [PMID:41641862] | Chambon C, Picard E, Zola M, Aichedo S, | Journal of proteome research | 2026 | 0 |
| Machine Learning and Blood-Targeted Proteomics Enable Early Prediction and Etiol [PMID:41683823] | Starodubtseva N, Tokareva A, Kononikhin | International journal of molec | 2026 | 0 |
| Club cell RhoA activation amplifies allergic airway inflammation by regulating e [PMID:41633491] | Tu W, Wu M, Wan R, Alphonse M, Gu W, Gho | The Journal of allergy and cli | 2026 | 0 |
| Identifying the hub genes in macrophage infiltration and verifying of the role o [PMID:41730938] | Tang L, Xu Y, Nong Z, Li F, Pan L | Scientific reports | 2026 | 0 |
| Molecular Insights Into Canine Hepatocellular Carcinoma: A Cross-Species Transcr [PMID:41664952] | Arif M, Hasan MN, Nozaki N, Ide Y, Akiya | Mol Carcinog | 2026 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and resc [PMID:39129007] | Chae S, Lee HJ, Lee HE, Kim J, Jeong YJ, | Journal of neuroinflammation | 2024 | 0 |
| Identification of crosstalk genes and immune characteristics between Alzheimer's [PMID:39188714] | An W, Zhou J, Qiu Z, Wang P, Han X, Chen | Frontiers in immunology | 2024 | 0 |
| Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. [PMID:35990663] | ["Feng C", "Shan M", "Xia Y", "Zheng Z", | Frontiers in immunology | 2022 | 0 |
| Evaluation method for cell-free in situ tissue-engineered vasculature monitoring [PMID:35436313] | ["Matsumura G", "Isayama N", "Sato H"] | PloS one | 2022 | 0 |
| Evidence that ageing yields improvements as well as declines across attention an [PMID:34413509] | ["Ver\u00edssimo J", "Verhaeghen P", "Go | Nature human behaviour | 2022 | 0 |
| [WALANT - Wide Awake Local Anaesthesia No Tourniquet: Complications in elective [PMID:35168268] | Wieschollek S, Forster S, Megerle K | Handchirurgie, Mikrochirurgie, | 2022 | 0 |
| Complement factor C1q mediates sleep spindle loss and epileptic spikes after mil [PMID:34516796] | Holden SS, Grandi FC, Aboubakr O, Higash | Science (New York, N.Y.) | 2021 | 0 |
| Adaptive learning algorithms to optimize mobile applications for behavioral heal [PMID:33657217] | Figueroa CA, Aguilera A, Chakraborty B, | Journal of the American Medica | 2021 | 0 |
| Engineering complex communities by directed evolution. [PMID:33986540] | Chang CY, Vila JCC, Bender M, Li R, Mank | Nature ecology & evolution | 2021 | 0 |